Risk Of Endometrial Cancer In Patients With Antipsychotic Agents ñ A Nationwide Study In Taiwan
Wei-Ling CHEN, , Taiwan (ROC)
HSIEH C. 1, 3, 4
1 Aging Medicine Program, China Medical University, Taichung, Taiwan
2 Department of Psychiatry, Taichung Veterans General Hospital, Taichung, Taiwan
3 Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan
4 Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
Increasing evidence indicates the potential genotoxic or carcinogenic effects of antipsychotics which increase carcinogenesis or promote tumor progression. The risk of developing cancer must be considered by psychiatrists in their prescriptions. However, the association between antipsychotic agents-treated patients and risk of endometrial cancer is unclear. The aim of the study is to assess the risk of endometrial cancer after antipsychotic agents treatment. A case control study by analyzing data from the National Health Insurance Research Database (NHIRD) in Taiwan was designed to understand the relationship between antipsychotic agents and endometrial cancer. Insurance claims data for 6516 endometrial cancer patients were randomly selected from all insured women in the NHIRD. After the risk factors of endometrial cancer such as hypertension, hyperlipidemia, diabetes malleus, and polycystic ovaries were adjusted, there was a statistically significant increased risk of endometrial cancer in chronic haloperidol users compared to other antipsychotic-agents users. However, the chronic sulpiride user had a statistically significant decrease risk of endometrial cancer. Besides, the risk of endometrial cancer was significantly lower in the chronic haloperidol users with the history of progesterone treatment than in the chronic haloperidol users without the history of progesterone treatment. These findings suggest the most common antipsychotic agent, haloperidol, is associated with the increased risk of developing endometrial cancer. Haloperidol combined with progesterone treatment may consider as a solution for haloperidol-increased risk of endometrial cancer.